

SILENT CARDIAC INVOLVEMENT IN RHEUMATIC DISEASE

NESLIHAN SEYREK*
MUSTAFA DEMIRTAS*
EREN ERKEN*
SAIME PAYDAS*
AHMET BIRAND*

SUMMARY: Silent cardiac involvement in rheumatic disease was studied in 61 patients with various rheumatic diseases and 15 healthy controls by noninvasive methods, including electrocardiogram, M-mode and 2 dimensional echocardiography, and systolic time intervals. Patients with Rheumatoid Arthritis and Ankylosing Spondylitis showed prolongation of QTc and QRS, respectively. Systolic time intervals were equal in both groups. A significant increase in left ventricular mass was found in patients with rheumatic diseases. Therefore we can conclude that these results support the silent cardiac involvement in rheumatic diseases.

Key Words : Rheumatic disease, silent cardiac involvement.

INTRODUCTION

The rheumatic diseases have many similar clinical features and are often classified together. Systemic inflammatory manifestations and acute or chronic arthritis occur in most patients. The etiology and pathogenesis of the rheumatic diseases have not been established yet. They all involve cardiovascular system to varying degrees. Pericarditis, myocarditis, endocarditis and conduction defects in are seen in patients with rheumatic diseases (16). Use of echocardiography has enabled much better diagnosis for cardiac involvement.

The purpose of this study is to investigate the extent of cardiovascular findings in some rheumatic

diseases, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS) and Behçet disease (BD), by noninvasive methods. Echocardiography, electrocardiography (EKG), and systolic time intervals (STI) were performed to identify the degree of cardiac involvement.

PATIENTS AND METHODS

Between 1988 and 1992, 61 patients (41 females, 20 males) and 15 normal controls (9 females, 6 males) were included in the study group. Out of 61 patients, 24 patients had RA, 10 patients had SLE, 15 patients had BD and 10 patients had AS. All of the patients fulfilled the American Rheumatism Association (ARA / criteria for RA, SLE, BD an AS (1-3,17).

The mean age for the patients was 35 years (range 19-55) it was 31 years (range 21-37) for the normals. After the physi-

*From Departments of Cardiology and Rheumatology, Çukurova University, School of Medicine, Adana, Türkiye.

cal examinations and the histories, the study group were checked for hematocrit (Hct), white blood count (WBC), serum glucose, urea, creatinine, ALT, AST, uric acid, alkaline phosphatase, ANA and RF, M-mode and 2 dimensional echocardiograms were recorded in the left lateral decubitus position. Ejection fraction (EF), cardiac output (CO), cardiac index (CI), fractional shortening (FS) and left ventricular mass (LVM) were measured by echocardiography. Echocardiographic dimensions were adjusted for body surface area according to the American Society of Echocardiography (15). Twelve-lead ECG was used and PR, QRS and QTc intervals were recorded. STI measurement for left ventricular performance was assessed by Hawlett Packard 8890-A phonocardiogram. The pre ejection period (PEP) the left ventricular ejection time (LVET) the total electromechanical interval (QS₂) and PEPL-

VET ratio were calculated according to Weissler regression index (20).

Left ventricular mass (LVM) was calculated by using the formula :

$LVM = [(Left\ ventricular\ end\ diastolic\ dimension + posterior\ wall\ thickness + interventricular\ septum\ thickness)^3 - (Left\ ventricular\ end\ diastolic\ dimension)^3] \times 1.05$.

Cardiac involvement was diagnosed with either ECG abnormality or echocardiographic abnormality.

Student's t tests were used for statistical analysis.


RESULTS

In 61 patients with rheumatic diseases arthritis (RA, SLE, BD and AS) cardiac involvement were compared with 15 normal controls. In RA group, the mean, QTc

Table 1: Comparison of clinical features in the rheumatic diseases and the controls.

Age (years)	RA 32.2±10 (19-59)	SLE 29.7±8.6 (20-46)	BD 30.7±7.2 (20-47)	AS 29.7±6.2 (20-43)	Control 31.1±5.7 (21-37)	Significant p<0.05
Sex (male/female)	-/24	-/12	11/4	9/1	6/9	
The mean duration of disease (year)	5(1-9)	4(1-10)	6(1-2)	8(1-7)		
Heart rate (beats/min)	82.7±9.6	90.6±11.3	80.0±18.1	81.4±15.4	83.2±8.2	p<0.05
Systolic blood pressure (mmHg)	128.7±20.2	126.7±21.9	118.0±16.6	117.5±13.6	120.3±9.7	
Diastolic blood pressure (mmHg)	78.9±12.1	80.0±12.2	77.7±14.0	74.0±9.7	76.7±4.9	p>0.05
ECG findings PR (msn)	148.3±32.2	140.0±21.1	136.0±25.3	136.0±20.6	142.7±18.3	p<0.02
QRS (msn)	76.7±16.3	80.0±0.0	82.2±10.3	104.0±20.6	77.3±28.1	p<0.02
QTc (msn)	411.7±30.8	393.2±14.4	397.1±175.8	382.4±32.6	391.4±18.8	p<0.03
Systolic time intervals PEP (msn)	137.3±24.1	146.0±17.1	159.9±25.7	150.0±15.4	143.8±17.8	p<0.05
LVETI (msn)	443.5±66.3	428.7±25.8	42.4±49.6	421.8±20.4	415.8±37.5	p>0.05
QS ₂ I (msn)	570.2±44.4	574.8±23.6	583.5±65.2	571.8±21.7	563.4±39.2	p>0.05
PEP/LVET (msn)	0.369±0.109	0.389±0.077	0.443±0.074	0.215±0.077	0.390±0.082	p>0.05
Echocardiographic measurements Pericardial effusion	2/24(8.3%)	3/12(25%)				
EF	0.58±0.19	0.66±0.07	0.59±0.14	0.57±0.12	0.65±0.05	p>0.05
CO (L/min)	4.17±1.8	5.7±1.6	4.7±2.3	4.9±1.3	4.2±1.3	p>0.05
CI (L/min/m ²)	2.5±1.2	3.7±1.3	2.7±1.3	2.8±0.6	2.3±0.6	p>0.05
PS (%)	34.2±12.7	36.7±5.0	33.7±9.8	33.0±8.5	36.0±2.9	p>0.05
LVM (g/m ²)	125.5±31.0	164.4±82.5	196.9±66.8	149.7±39.1	96.5±13.6	p>0.001

Figure 1: LVM measurements in each group.



interval was significantly longer than both the other groups and the controls ($p < 0.03$). On the other hand, in AS group, the mean QRS interval was significantly longer than both the other groups and the controls ($p < 0.05$). Systolic time intervals, blood pressure and heart rate measurements were similar in each group.

Echocardiographic signs of pericardial effusion were found in two patients (%8.3) with RA and three patients (%25) with SLE. Echocardiographic measurements (EF, CO, CI, FS) were similar in each group, except LVM. The mean LVM was significantly increased in all groups (RA, SLE, BD and AS) compared to normals. In BD, it was even more significant than it was in the other rheumatic diseases (Table 1).

LVM values were shown in Figure 1.

QTc longer than 420 msn was found in 8 of 24 RA (33%) patient QRS longer than 120 msn was found in 6 of 10 AS (60%) patients.

DISCUSSION

Cardiac involvement in patients with rheumatic diseases has been emphasized since 1881 (4). Cardiac manifestations have been investigated in clinically asymptomatic patients by postmortem and pathological studies. With the use of modern noninvasive techniques, cardiac involvement in rheumatic diseases has become more frequent in recent studies. Especially echocardiography has a unique role in analyzing mor-

phological and functional changes of the heart in patients with these diseases.

Cardiac disease in RA is seen as pericarditis (11-50%), myocarditis (19%), endocardial inflammation, conduction defects and coronary arthritis (11,13,14,19). In one study, increased LVM were observed in 182 RA patients, whereas STI, EF, blood pressure and ECG findings were in normal limits (19). In our study, we demonstrated prolongation of QTc interval increased LVM and 8.3% pericardial effusion in patients with RA. Left ventricular dysfunction is accompanied by vagal autonomic neuropathy of RA, slight anemia, chemical mediators of inflammation, NSAIDs and endogenous catecholamines (12,21). These findings were indicator of cardiac involvement in clinically asymptomatic patients with RA in our study.

Pericarditis (80%) is the most common cardiac manifestation in SLE, and the others are myocarditis (8-18%), endocarditis (16-44%) and conduction defects (34-70%) (5,6,16). We detected pericarditis (25%) and an increased in LVM in patients with SLE. It has been suggested that an altered hemodynamic state is caused by the disease itself or its treatment (NSAIDs) and cardiac involvement may be found in clinically asymptomatic patients with SLE.

Cardiac involvement in BD is 7-29%, and pericarditis, myocarditis and arrhythmias have been reported in literature (8,9). We found increased LVM in BD. We

suggested that these findings might be related to myocardial involvement of BD.

Ankylosing spondylitis is a common disease and the degree of cardiac involvement in AS has been described as aortic insufficiency (20%), aortitis, conduction disturbance (5-33%), cardiomyopathy and altered diastolic function. In our study although 10 patients with AS had no cardiac abnormality (7,10,18) on clinical examination, we investigated prolongation of QRS interval and increased LVM in patients with AS.

In conclusion, by noninvasive techniques, we demonstrated cardiac involvement in patients with RA, SLE, BD and AS, although they were all clinically asymptomatic cardiac wise. This is a preliminary study and there is also a need for a multicentre, prospective clinicopathological study for cardiac involvement in rheumatic diseases. Asymptomatic patients with rheumatic disease show definite cardiac abnormalities by ECG, STI and echocardiographic evaluation. Follow up studies could help one understand the natural history and importance of these abnormalities.

REFERENCES

1. Arnett FC, et. al. : *The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 31:315, 1988.*
2. Behçet H : *Über rezidivierende Aphthose, durch ein virus verursachte Geschwüre am mund am Auge und an des Genitalien. Derm Wschr, 105:1152, 1937.*
3. Bennet PH and Wood PHN : *Population studies of the rheumatic diseases. Proceedings of the Third International Symposium. Amsterdam, Excerpta Medica, p 456, 1968.*
4. Charcot JM : *Clinical lectures on senile and chronic disorders. The Ne Sydenham Society, 95:172, 1881.*
5. Crozier IG, Li E, Milne MJ and Nichols G : *Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol, 65:1145, 1990.*
6. Doherty NA, Feldman G, Maurer G and Siegel RJ : *Echocardiographic findings in systemic lupus erythematosus Am J Cardiol, 61:1144, 1988.*
7. Gragham DC and Smythe HA : *The carditis and aortitis of ankylosing spondylitis. Bull Rheum Dis, 9:171- 1958.*
8. Higashihara M, Mori M, Takeuchi A, et. al. : *Myocarditis in Behçet's disease a case report and review of the literature. J Rheumatol, 9:630, 1982.*
9. James DG and Thomson A : *Recognition of the diverse cardiovascular manifestations in Behçet's disease. Am Heart J, 13:45, 1982.*
10. Khan AM, Sun JP and Balher RC : *Echocardiographic evidence of altered cardiac diastolic function in ankylosing spondylitis. The Lancet, 27:1501, 1987.*
11. Lebowitz WB : *The heart in rheumatoid arthritis (rheumatoid disease). A clinical and pathological study of 62 case. Ann Intern Med, 58:102, 1963.*
12. Leden I, Eriksson A, Lilja B, Sturfelt G, et. al. : *Autonomic nerve function in rheumatoid arthritis of varying severity. Scand J Rheumatol, 12:166, 1983.*
13. MacDonald J Jr, Crawford MH, Krippel JH, Zvaifler NJ and O'Rourke RA : *Echocardiographic assessment of cardiac structure and function in patients with rheumatoid arthritis. Am J Med, 63:890, 1977.*
14. Prakash R, Atassi A, Poske R and Rosen KM : *Prevalence of pericardial effusion and mitral value involvement in patients with rheumatoid arthritis without cardiac symptoms. N Engl J Med, 289:597, 1973.*
15. Sahn DJ, Demaria A, Kissio J and Weyman A : *The committee on M-mode standardization of the American Society of Echocardiography. Recommendation regarding quantitation in M-mode echocardiography : Results of a Survey of echocardiographic measurements. Circulation, 58:1072, 1978.*
16. Stollerman GH : *Rheumatic and heritable Connective tissue disease of the cardiovascular system. Heart Disease. Braunwald, WB Saunders Company (3th Ed). Philadelphia, pp 176-1733, 1988.*
17. Tan EM, Cohen AS, Fries JF, et. al. : *The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 25:1271, 1982.*
18. Thomas D, Hill W, Gaddes R, et. al. : *Early detection of aortic dilatation in ankylosing spondylitis using echocardiography. Aust N Z J Med, 12B 10, 1982.*
19. Voipio-Pulki LM and Saraste M : *Left ventricular function in rheumatoid arthritis. European Heart J, 8(Supplement J):105, 1987.*
20. Weissler AM, Harris WS and Schoenfeld CD : *Systolic time intervals in heart in man circulation 37:149, 1968.*
21. Wennmalm A : *Prostaglandins and cardiovascular function. Some biochemical and physiological aspects. Scand J Clin Lab Invest, 39:399, 1979.*

Correspondence:

Neslihan Seyrek

Departments of Cardiology and Rheumatology,
Çukurova University, School of Medicine,
Adana, TÜRKIYE.